FOXP3 and colorectal carcinoma: About them, a recent study showed that CRC patients can be separated into two groups: (i) with tumors infiltrated predominantly by suppression-competent effectors Tregs and (ii) with tumors infiltrated with a sizable fraction of Foxp3+ non-Tregs in addition to effectors Tregs (62).